NFE2L2 and diabetes mellitus: Furthermore, treatment of db/db and streptozotocin-induced diabetic mouse models with CDDO derivatives improves diabetes outcome (105–107) and these compounds have been tested under several clinical trials to improve chronic kidney disease in diabetic patients (7).This places NRF2 as a potential therapeutic target for type-2 diabetes.